Abstract
BackgroundAlthough triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. This study aimed to assess the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients and the effectiveness of triptorelin on LUTS.MethodsIn this 48-week multicenter, non-interventional, prospective study, we enrolled patients with locally advanced or metastatic prostate cancer. Patients received triptorelin (15 mg) intramuscularly at baseline and at weeks 12, 24, and 36 with symptom assessment using the International Prostate Symptoms Score (IPSS). The primary endpoints were the prevalence of LUTS at baseline per IPSS categories and the percentage of patients with moderate to severe LUTS (IPSS > 7) at baseline, having at least a 3-point reduction of IPSS score at week 48.ResultsA total of 398 patients were included; 211 (53.0%) and 160 (40.2%) among them had severe and moderate LUTS, respectively. Of the patients with IPSS scores available at baseline and at week 48 (n = 213), 81.2% achieved a reduction in IPSS of at least 3 points. Of the patients with moderate to severe LUTS at baseline and IPSS scores available at baseline and at week 48 (n = 194), 86.6% achieved a total IPSS reduction of at least 3 points.ConclusionsThe vast majority of Chinese patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin as part of their standard treatment have severe or moderate LUTS. Triptorelin therapy resulted in sustained improvement of LUTS in these patients.
Highlights
Triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear
We carried out this multicenter, noninterventional, prospective study to evaluate the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients scheduled to receive triptorelin and to examine the effectiveness of triptorelin on LUTS
Patients were excluded if they had hypersensitivity to triptorelin or one of its excipients, if they were at risk of a serious complication in case of a tumour flare, had received another experimental drug over the last 3 months before the study, had received a luteinizing hormone-releasing hormone (LHRH) analogue in the preceding 6 months, or had a life expectancy < 12 months
Summary
Triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. Despite considerable improvements in the control of localized disease, one third of patients diagnosed with prostate cancer will progress to Triptorelin is an agonist of natural GnRH with increased duration of action and higher affinity for the pituitary. He et al BMC Urology (2018) 18:23 receptor compared with the parent compound [7]. Prostate cancer often does not cause symptoms; some patients do present with symptoms, the actual incidence of this malignancy is unknown We carried out this multicenter, noninterventional, prospective study to evaluate the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients scheduled to receive triptorelin and to examine the effectiveness of triptorelin on LUTS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
